Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-02-13Clinical Trial Update: Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib [Phase 4]
Phase 4 trial evaluating imatinib for chromosome abnormalities in chronic myeloid leukemia and for gastrointestinal stromal tumors has been …
-
CLINICAL_TRIALS trial_result · 2009-01-29Clinical Trial Update: Stem Cell Transplantation for Patients With Hematologic Malignancies [Phase 3]
A Phase 3 clinical trial evaluating stem cell transplantation for hematologic malignancies has completed. The study covered several conditio…
-
CLINICAL_TRIALS trial_result · 2009-01-29Clinical Trial Update: Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies [Phase 2]
Phase 2 clinical trial update on stem cell transplantation as immunotherapy for hematologic malignancies. The trial status is completed.
-
CLINICAL_TRIALS trial_result · 2009-01-26Clinical Trial Update: Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT [Phase 2]
A Phase II trial evaluating busulfan and fludarabine as preparative conditioning therapy in adults with hematopoietic disorders undergoing m…
-
CLINICAL_TRIALS trial_result · 2008-12-30Clinical Trial Update: Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) [Phase 2]
Phase 2 feasibility and efficacy study of a conditioning regimen using fludarabine, busulfan, and total body irradiation before allogeneic h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2008-12-19FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) from Novartis Pharmaceuticals Corporation, resulting in regulatory a…
-
CLINICAL_TRIALS trial_result · 2008-11-27Clinical Trial Update: Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia [Phase 4]
Phase 4 trial comparing Glivec (imatinib) monotherapy versus Glivec plus interferon alfa in chronic-phase chronic myeloid leukemia; the stud…
-
CLINICAL_TRIALS withdrawal · 2008-10-31Clinical Trial Update: A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia [Phase 2]
Phase 2 trial evaluating CLAG with imatinib (Gleevec) for refractory/relapsed chronic myeloid leukemia and acute myeloid leukemia has been w…
-
CLINICAL_TRIALS trial_result · 2008-10-07Clinical Trial Update: Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia [Phase 2]
A Phase 2 clinical trial evaluating modified bone marrow stem cell transplantation for chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS research · 2008-03-04Clinical Trial Update: The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies
This is a National Cancer Institute clinical trial update describing the collection of peripheral blood lymphocytes and marrow progenitor ce…
-
CLINICAL_TRIALS trial_result · 2007-12-17Clinical Trial Update: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Phase 2]
Phase II trial of decitabine in patients with chronic myeloid leukemia in the accelerated phase who are refractory to imatinib mesylate has …
-
FDA approval · 2007-11-08FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories.
-
FDA approval · 2007-10-29FDA Approved: TASIGNA — Original Application (Novartis Pharmaceuticals Corporation)
FDA approved Tasigna (nilotinib) through the original application (NDA022068) for Philadelphia chromosome-positive chronic myeloid leukemia.…
-
CLINICAL_TRIALS trial_result · 2007-10-10Clinical Trial Update: Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy [Phase 3]
Phase 3 trial comparing imatinib alone to imatinib plus pegylated interferon in Philadelphia-positive chronic myeloid leukemia patients with…
-
FDA approval · 2007-09-13FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA supplemental application submitted for GLEEVEC (imatinib mesylate) by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2007-08-10Clinical Trial Update: Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase [Phase 2]
A Phase 2 trial of STI571 (imatinib) for Ph+ chronic myeloid leukemia in accelerated and blastic phase has completed.
-
CLINICAL_TRIALS trial_result · 2007-08-10Clinical Trial Update: Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) [Phase 3]
A Phase 3 trial compared standard-dose Imatinib (400 mg daily) with high-dose Imatinib (800 mg daily) in chronic myeloid leukemia and has co…
-
CLINICAL_TRIALS trial_result · 2007-08-03Clinical Trial Update: Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase [Phase 2]
A Phase 2 exploratory study evaluating high-dose imatinib in intermediate-risk chronic myeloid leukemia in chronic phase has completed.
-
CLINICAL_TRIALS trial_result · 2007-08-03Clinical Trial Update: Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) [Phase 2]
A Phase 2 study evaluating the combination of STI571 (imatinib) and pegylated interferon alfa-2b (PegIntron) for chronic myeloid leukemia wa…
-
CLINICAL_TRIALS trial_result · 2007-08-03Clinical Trial Update: Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial evaluating STI571 (imatinib) for Philadelphia chromosome–positive chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS research · 2007-04-27Clinical Trial Update: AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year [Phase 2]
Phase 2 trial evaluating combination therapy of imatinib mesylate and alpha-2a interferon for chronic phase CML patients who are resistant o…
-
CLINICAL_TRIALS trial_result · 2007-04-12Clinical Trial Update: Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers [Phase 1, Phase 2]
Completed Phase 1/2 clinical trial assessing infusion of ex vivo treated umbilical cord blood stem cells following chemoradiation in patient…
-
FDA approval · 2006-10-19FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2006-09-19FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)
FDA approves a supplemental application for DROXIA (hydroxyurea) submitted by Waylis Therapeutics LLC.
-
FDA approval · 2006-08-15FDA Approved: HYDROXYUREA — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for HYDROXYUREA submitted by Endo USA, Inc.